These boards are cropping up around the US as neurologists acclimate to a new class of drugs, but not everyone agrees such ...
Drug cost-effectiveness organisation ICER has revised its view of Eisai’s new Alzheimer’s disease therapy Leqembi, but has concluded that the price set by the pharma group is still too high.